Myelodysplastic Syndrome

MD IQ

News

Combo worsens platelet recovery in MDS

Results from the phase 3 SUPPORT trial suggest there is no role for the combination of eltrombopag and azacitidine in patients with intermediate-...

Conference Coverage

When is it CMML?

DUBROVNIK, CROATIA – Dr. Nadira Durakovic offers her tips for differentiating between CMML and other look-alike disorders.

News

HIF1A could be therapeutic target for MDS

The transcription factor HIF1A could be a therapeutic target for “a broad spectrum” of patients with myelodysplastic syndromes (MDS), according to...

Pages